Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) subsidiary, Oravax Medical, reported positive preliminary data from its Phase 1 trial of an oral COVID-19 vaccine candidate.
Oravax Medical is developing oral vaccines that combine Oramed’s POD technology with Premas Biotech’s D-Crypt platform. The oral COVID-19 vaccine candidate is designed using D-Crypt technology as a triple antigen VLP vaccine that targets three major surface proteins of the SARS-CoV-2 virus: spike, membrane and envelope.
This should allow the oral vaccine candidate to trigger a protective response not only against the prevalent strains of the SARS-CoV-2 virus, but also the emerging mutations, the company said in a statement.
Nadav Kidron, chairman of Oravax and CEO of Oramed, said the initial data indicates that “our platform can be safely and successfully used to orally deliver protein-based vaccines.”
Dr. Prabuddha Kundu, co-founder and managing director for Premas Biotech, said these results, together with the recent evolution of the Covid strains, “further raise our confidence in the success of an oral COVID-19 vaccine and the broad potential of our platform, along with Oramed’s POD platform, to explore oral vaccines for other infectious diseases.”